Lv2
136 积分 2022-02-17 加入
BCMA T-Cell Engager Therapy in Patients with Refractory Autoimmune Disease
1个月前
已完结
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
1个月前
已完结
Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma
2个月前
已完结
Which One Is Better for Relapsed/ Refractory Acute Myeloid Leukemia: Daratumumab or CD38-Targeted Chimeric Antigen Receptor T-Cell Therapy?
2个月前
已关闭
Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network
2个月前
已完结
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma
2个月前
已完结
Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study
2个月前
已关闭
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
3个月前
已完结
皖公网安备34019202002308
